SciBase Reports Significant Growth and New Milestones in Q3 2026

SciBase Sees Remarkable Growth in Q3 2026

In its latest interim report, SciBase, a pioneering medical technology company in dermatology, shared exciting news about its financial performance and significant milestones achieved in the third quarter of 2026. The company reported net sales of TSEK 14,621, showcasing a robust increase of 41%, which adjusted for currency effects jumps to an impressive 45%.

However, it wasn't all positive, as the company faced a loss after tax amounting to TSEK 25,768, a rise from TSEK 18,170 the previous year. This resulted in a loss per share of SEK 2.52, compared to SEK 4.66 for the same quarter last year.

Despite these challenges, SciBase's underlying performance revealed numerous strengths. The gross margin improved to 72.3% from 69.5%, signaling efficient production processes. Additionally, electrode sales volume surged by 36%, equating to 28,896 units sold, while repeat sales to existing customers increased by an impressive 40%.

Over the first three quarters of the year, total net sales reached TSEK 44,207, representing a 58% increase from 27,987 in 2025, again highlighting the company’s resilience in the market despite the losses reported.

Important Milestones Achieved

Among the key highlights of the quarter, SciBase saw its sales in the US skin cancer market soar by 68%. They also made strides in Germany's skin cancer segment, which grew by 18% compared to the previous quarter. Such impressive growth in specific markets points to the company's increasing footprint in dermatological markets across the globe.

Moreover, the quarter witnessed notable developments with the product Nevisense, which utilizes Artificial Intelligence (AI) coupled with advanced Electrical Impedance Spectroscopy (EIS) technology aimed at enhancing diagnostic accuracy in skin assessments. A significant accomplishment in this regard was the submission of a premarket notification to the U.S. Food and Drug Administration (FDA), seeking to expand the indication for Nevisense to include the assessment of non-melanoma skin cancers.

This initiative is anticipated to bolster the company's market position significantly, given the rising demand for non-invasive skin assessment technologies. Securing this FDA clearance is a critical step for SciBase, as it not only affirms the product's validity but also opens new opportunities for business growth.

Financial Strategies and Future Outlook

In addition to new product developments, SciBase's management board approved a fully underwritten rights offering valued at approximately MSEK 57.5. These funds are earmarked to support the company’s development and operational expansion.

Looking forward, the company has initiated collaborations to further research in dermatology, particularly in a pivotal study with the National Institutes of Health (NIH) and the Swiss Institute of Allergy and Asthma Research (SIAF). This study focuses on understanding how environmental exposure affects skin health, using SciBase's Nevisense technology as a primary endpoint.

As the quarter concluded, SciBase managed to secure its first US payer coverage through a significant insurance partnership, marking a monumental achievement for the company. Insurers now recognize the company's non-invasive skin assessment technology, indicative of its mainstream acceptance within the medical community.

In summary, despite facing financial losses, SciBase is steering towards promising growth with substantial increases in sales, strategic collaborations, and innovative product advancements, reinforcing its position as a leader in dermatological medical technology. The company remains committed to pioneering advancements to enhance skin health management, aiming to reduce healthcare costs while improving patient outcomes.

About SciBase

SciBase is a pioneering medical technology company focusing on early detection and prevention in dermatology. By harnessing advanced technologies and a commitment to clinical excellence, SciBase aims to revolutionize skin health management.